What Is Saccharomyces boulardii?
Saccharomyces boulardii is a probiotic yeast that differs from typical bacterial probiotics in several important ways. French microbiologist Henri Boulard discovered it in the 1920s in Southeast Asia, where he observed locals drinking lychee peel tea to treat diarrhea.
Unlike bacterial probiotics (such as Lactobacillus and Bifidobacterium), S. boulardii is naturally resistant to antibiotics — meaning it can be taken alongside antibiotic courses without being destroyed by the medication.
Who this guide is for: Anyone considering S. boulardii during antibiotic courses, for preventing traveler's diarrhea, or for general gut support.
TL;DR
- S. boulardii is one of the few probiotics with strong clinical evidence
- Best evidence: preventing antibiotic-associated diarrhea (McFarland, 2010)
- Typical dose: 250–500 mg (5–10 billion CFU) once or twice daily
- Can be used with antibiotics — antibiotics don't destroy yeast
- Generally well-tolerated, but avoid in severely immunocompromised patients
- Do not use if you have a yeast allergy
How S. boulardii Works
The mechanism of action is multilayered and surprisingly well-studied:
1. Pathogen binding — S. boulardii directly binds to pathogenic bacteria, including Clostridium difficile toxins, neutralizing them (Czerucka et al., 2007)
2. Mucosal protection — stimulates intestinal immunoglobulin A (IgA) production, strengthening the barrier function
3. Anti-inflammatory effect — inhibits the NF-kB signaling pathway, reducing pro-inflammatory cytokine production
4. Enzymatic activity — produces a protease that degrades Clostridium difficile toxins A and B
An important distinction: S. boulardii does not permanently colonize the gut. It passes through the digestive tract and exerts its effects temporarily, typically clearing within 3–5 days after discontinuation (Elmer et al., 1999).
When S. boulardii Truly Helps
Antibiotic-Associated Diarrhea
This is the most strongly evidenced use case. A meta-analysis (Szajewska & Kolodziej, 2015) of 21 randomized trials showed that S. boulardii reduces the risk of antibiotic-associated diarrhea by approximately 50%. This is both statistically and clinically significant.
Practical advice: Start S. boulardii on the same day as your antibiotic course and continue for 1 week after the course ends.
Clostridium difficile Infection
S. boulardii has shown effectiveness in preventing recurrent C. difficile infections. A meta-analysis by McFarland (2010) demonstrated significant reduction in recurrence risk. However, it is not suitable as first-line treatment for active C. difficile infection — antibiotic therapy is still necessary.
Acute Diarrhea in Children
Multiple studies have shown that S. boulardii shortens acute diarrhea duration in children by an average of 1 day (Feizizadeh et al., 2014). The WHO recommends probiotic use in diarrhea treatment alongside rehydration.
When S. boulardii Does Not Help
- Irritable bowel syndrome (IBS) — evidence is conflicting. Some small studies show relief, but large trials have not confirmed the effect.
- Weight loss — no evidence.
- General immune boosting — indirect effects are possible, but direct evidence is lacking.
Dosage
| Indication | Dose | Duration | Notes |
|---|---|---|---|
| During antibiotic course | 250–500 mg 2x daily | Course duration + 1 week | Take 2 hours apart from antibiotics |
| Traveler's diarrhea prevention | 250 mg 1x daily | 5 days before travel until end | Start before travel |
| Acute diarrhea | 250–500 mg 2x daily | Until symptoms resolve | Max 5–7 days |
| C. difficile recurrence prevention | 500 mg 2x daily | 4 weeks | Alongside antibiotic therapy |
Important: CFU (colony-forming unit) count matters more than milligrams. Look for at least 5 billion CFU per serving.
How to Choose a Product
What to Look For:
1. CFU count — at least 5 billion CFU per serving
2. Strain identification — look for a specific strain name (e.g., CNCM I-745 or CNCM I-3799), not just "S. boulardii"
3. Storage conditions — some forms require refrigeration, others are shelf-stable
4. Capsule vs powder — acid-resistant capsules are preferred, though S. boulardii tolerates stomach acid well regardless
5. Price — In Estonia €8–20 (30–60 capsules); cheapest isn't always worst
Side Effects and Warnings
- Generally well-tolerated — side effects are rare and mild (gas, bloating)
- Fungemia risk — extremely rare, but documented in severely immunocompromised patients and hospitalized patients with central venous catheters (Enache-Angoulvant & Hennequin, 2005)
- Yeast allergy — if allergic to yeast, avoid S. boulardii
- Pregnancy and breastfeeding — data is limited, consult your doctor
Frequently Asked Questions
Can S. boulardii be taken with antibiotics?
Yes, this is one of its main advantages. Since it's a yeast, not a bacterium, antibiotics don't destroy it. However, it's still advisable to take it 2 hours apart from antibiotics.
How long does S. boulardii stay in the body?
S. boulardii does not permanently colonize the gut. It typically clears within 3–5 days after discontinuation (Elmer et al., 1999).
Is S. boulardii safe for children?
Yes, multiple studies have demonstrated safety and efficacy in children (from age 1) for acute diarrhea treatment. Consult your pediatrician regardless.
How does S. boulardii differ from Lactobacillus?
S. boulardii is a yeast, not a bacterium. This means: antibiotic resistance, different mechanisms of action, and temporary (not permanent) gut colonization. Both have their place — they're complementary, not competing.
Does S. boulardii help after food poisoning?
Direct evidence for treating food poisoning is insufficient. However, it may help accelerate gut recovery after an acute episode.
Estonia-Specific Notes
In Estonian pharmacies, S. boulardii is primarily known under the brand names Enterol and Precosa, priced at €8–15 for 30 capsules. Supplement alternatives are also available, often at lower prices. While antibiotic use in Estonia is below the European average, recommending probiotics alongside antibiotic courses is an increasingly common practice.
References
- Czerucka D, Piche T, Rampal P (2007). Review article: yeast as probiotics — Saccharomyces boulardii. Alimentary Pharmacology & Therapeutics, 26(6), 767–778.
- Elmer GW, McFarland LV, Surawicz CM, Danko L, Greenberg RN (1999). Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Alimentary Pharmacology & Therapeutics, 13(12), 1663–1668.
- Enache-Angoulvant A, Hennequin C (2005). Invasive Saccharomyces infection: a comprehensive review. Clinical Infectious Diseases, 41(11), 1559–1568.
- Feizizadeh S, Salehi-Abargouei A, Akbari V (2014). Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics, 134(1), e176–e191.
- McFarland LV (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World Journal of Gastroenterology, 16(18), 2202–2222.
- Szajewska H, Kolodziej M (2015). Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Alimentary Pharmacology & Therapeutics, 42(7), 793–801.
Browse S. boulardii and probiotic products at MaxFit.
See also:
